NATIONAL CANCER POLICY FORUM

Innovative Person-Centered Clinical Cancer Research: A Workshop

September 29-30,2025

National Cancer Policy Forum
Forum on Drug Discovery, Development, and Translation

Workshop Website

Keck Center Room 100
500 Fifth Street, NW
Washington, DC 20001

MONDAY, SEPTEMBER 29, 2025 EASTERN TIME ZONE	
8:00 am	**Registration** (30 minutes)
8:30 am	**Welcome and Introductory Remarks** (10 minutes) Gwen Darien *(Participating Virtually)* and Lawrence Shulman, Planning Committee Co-Chairs
8:40 am	**Keynote: The Current State of the Science of Person-Centered Clinical Research** (~25 minutes) • Monica Bertagnolli, Harvard Kennedy School of Government *(Participating Virtually)*
9:05 am	**Session 1: Roundtable Discussion: Integrating Person-Centeredness into Clinical Cancer Research** (~1 hour, 35 minutes) *Co-Moderators:* *Gwen Darien, Patient Advocate Foundation (Participating Virtually)* *Randy Jones, University of Virginia* *Session Objective:* Discuss the challenges and opportunities of person-centered clinical research, including pharmacological and non-pharmacological clinical trials and population-based research across the cancer care continuum, from the perspectives of patients and caregivers. **Panelists** • Ricki Fairley, Touch: The Black Breast Cancer Alliance (BBCA) (~7 minutes) • Julia Maués, Guiding Researchers and Advocates to Scientific Partnerships (GRASP) (~7 minutes) • Ji Im, CommonSpirit Health (~7 minutes) • Susan Mazanec, Case Western Reserve (~7 minutes) **Panel Discussion and Audience Q&A** (~60 minutes)
10:40 am	**Break** (15 minutes)
10:55 am	**Session 2: Designing and Operationalizing Person-Centered Clinical Cancer Research** (~1 hour, 35 minutes) *Co-Moderators:* *Lawrence Shulman, University of Pennsylvania* *Gail Eckhardt, Baylor College of Medicine*

	Session Objective: Examine the challenges and opportunities of person-centered clinical research, broadly defined to include pharmacological and non-pharmacological clinical trials and population-based research across the cancer care continuum, from the perspective of researchers. **Patient-Reported Outcomes for Evaluating Toxicities (Adverse Events) in Cancer Clinical Research** (~10 minutes) • Ethan Basch, University of North Carolina at Chapel Hill **Assessing Symptoms and Functioning in Clinical Cancer Research to Evaluate Treatment Benefit** (~10 minutes) • Bryce Reeve, Duke University School of Medicine **Hybrid Decentralization Model for Early Phase Clinical Cancer Research** (~10 minutes) • Pat LoRusso, Yale University *(Participating Virtually)* **Facilitating Clinical Trials in Under-Resourced and Rural Areas** (~10 minutes) • Ruma Bhagat, Genentech **Engaging the Community in Clinical Cancer Research** (~10 minutes) • Howard "Skip" Burris, Sarah Cannon Research Institute **Panel Discussion and Audience Q&A** (~45 minutes)
12:30 pm	**Break** (1 hour)
1:30 pm	**Session 3: Building the Evidence Base for Person-Centered Clinical Cancer Research** (~1 hour, 35 minutes) *Co-Moderators:* *Roy Herbst, Yale University* *Robert Winn, Massey Comprehensive Cancer Center, Virginia Commonwealth University* *Session Objective:* Discuss lessons learned to inform and guide the next steps for robust evidence generation to improve person-centered clinical research and make clinical trials more efficient. **Overview: Person-Centered Standard and Pragmatic Clinical Trial Designs** (~10 minutes) • Roy Herbst, Yale School of Medicine **Learnings from PCORI's Foundational Expectations for Partnerships in Research** (~10 minutes) • Kristin Carman, Patient-Centered Outcomes Research Institute (PCORI) **Recruitment and Retention of Diverse Populations in Clinical Cancer Research** (~10 minutes) • Chanita Hughes-Halbert, University of Southern California **Insights from the European Organisation for Research and Treatment of Cancer** (~10 minutes) • Claire Piccinin, European Organisation for Research and Treatment of Cancer *(Participating Virtually)* **Panel Discussion and Audience Q&A** (~45 minutes)
3:05 pm	**Break** (15 minutes)

3:20 pm	**Session 4: Regulatory and Structural Considerations in the Design of Clinical Cancer Research** (~1 hour, 40 minutes) *Co-Moderators:* *Richard Schilsky, University of Chicago* *Cleo Ryals, Flatiron Health* *Session Objective:* Discuss the regulatory and structural considerations related to the design of clinical cancer research. **Engaging the National Clinical Trials Network Clinical Trial Groups** (~20 minutes) • Richard Schilsky, University of Chicago • Deborah Collyar, Patient Advocates In Research **Aligning the Goals of Industry and Publicly Funded Clinical Cancer Research With the Goals of Patients** (~10 minutes) • Lawrence Shulman, University of Pennsylvania **Person-Centeredness in Early Phase Clinical Cancer Research** (~10 minutes) • Shivaani Kummar, Oregon Health and Science University **A Pharmaceutical Industry Perspective** (~10 minutes) • Arun Balakumaran, Pfizer Inc. **Regulatory Use of Patient-Reported Outcomes in Oncology** (~10 minutes) • Vishal Bhatnagar, U.S Food and Drug Administration **Panel Discussion and Audience Q&A** (~40 minutes)
5:00 pm	**Adjourn and Reception**

TUESDAY, SEPTEMBER 30, 2025 EASTERN TIME ZONE	
8:00 am	**Registration** (30 minutes)
8:30 am	**Day 2 Welcome** (5 minutes) Lawrence Shulman, Planning Committee Co-Chair
8:35 am	**Session 5: Reporting Findings from Clinical Cancer Research Back to Participants** (~1 hour, 40 minutes) *Co-Moderators:* *Shivaani Kummar, Oregon Health and Science University* *Larissa Nekhlyudov, Brigham & Women's Hospital, Dana-Farber Cancer Institute; Harvard Medical School* *Session Objective:* Examine opportunities and challenges for reporting the findings from clinical cancer research and examine different methodologies for return of results to participants. **Patient Advocacy and Engagement Perspective** (~10 minutes) • Sarah Greene, Cancer Research Advocate **Clinical Bioethics Perspective** (~10 minutes) • Gregory Abel, Dana-Farber Cancer Institute; Harvard Medical School **Research Perspective** (~10 minutes)

	• Jeff Yorio, Texas Oncology **A Pharmaceutical Industry Perspective** (~10 minutes) • Edgar Braendle, AVEO Oncology **Reporting Findings in NCI Prevention and Screening Clinical Trials** (~10 minutes) • Lori Minasian, National Cancer Institute **Panel Discussion and Audience Q&A** (~50 minutes)
10:15 am	**Break** (15 minutes)
10:30 am	**Session 6: Summary Discussion with Co-Moderators: Advancing Progress in Person-Centered Clinical Cancer Research** (~1 hour) *Co-Moderators:* *Gwen Darien, Patient Advocate Foundation (Participating Virtually)* *Lawrence Shulman, University of Pennsylvania* Session co-moderators reconvene to summarize key observations and opportunities Session 1: Gwen Darien and Randy Jones Session 2: Lawrence Shulman and Gail Eckhardt Session 3: Roy Herbst and Rob Winn Session 4: Richard Schilsky and Cleo Ryals Session 5: Shivaani Kummar and Larissa Nekhlyudov
11:30 am	**Adjourn**

You may also scan the QR code below to submit questions and comments.
Please state your name and affiliation prior to asking a question.